114 results about "Specific immunotherapy" patented technology

The present invention provides methods for treating, preventing or reducing the severity of allergic reactions. The present invention also provides methods for enhancing the efficacy and/or safety of an allergen-specific immunotherapy (SIT) regimen. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4Rα) antagonist such as an anti-IL-4Rα antibody.

Methods and compositions of the invention relate to the enhancement of specific immunotherapies in cancer treatment. In particular, aspects of the invention relate to novel approaches to boost immune function using a complex carbohydrate pharmaceutical compound alone or in combination with other targeted immunotherapy to increase the efficacy of immunotherapy of cancer.

Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1 polypeptide; or a T cell that specifically reacts with a WT1 polypeptide. Such compositions may be used, for example, for the prevention and treatment of metastatic diseases.

Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise a WT1 polypeptide comprising an immunogenic portion of WT1, wherein said WT1 polypeptide comprises the polypeptide of SEQ ID NO:144. Such compositions may be used, for example, for the prevention and treatment of metastatic diseases.

Novel therapeutic immunotherapy compositions comprising at least two vectors, each vector encoding a functional CAR, whereby the combination of vectors results in the expression of two or more non-identical binding domains, wherein each vector encoded binding domain(s) are covalently linked to a transmembrane domain and one or more non-identical intracellular signaling motifs are provided herein as well as are methods of use of same in a patient-specific immunotherapy that can be used to treat cancers and other diseases and conditions.

Provided herein are compositions comprising anti-HLA-Ib antibodies as IVIg mimetics and methods for using the same for the prevention, treatment, therapy and/or amelioration of inflammation induced diseases and allograft rejection. In certain embodiments, the anti-HLA-Ib antibodies (monoclonal antibodies or mixed monoclonal antibodies, recombinant or chimeric or humanized or human antibodies) strongly mimic IVIg in immunoreactivity to HLA class Ia (HLA-A, HLA-B and HLA-Cw) and Ib antigens (HLA-E, HLA-F and HLA-G). In certain embodiments, the anti-HLA-Ib antibodies (monoclonal or mixed monoclonal antibodies; recombinant, chimeric, humanized or human antibodies) strongly mimic IVIg in immunomodulatory or immunosuppressive activities. While anti-HLA-Ib mAbs can be used to restore anti-tumor activities of CD8+ T cells and Natural killer cells by passive therapy in cancer patients, methods are also provided herein to induce production of polyclonal anti-HLA-Ib antibodies in cancer patients for restoring anti-tumor activities of CD8+ T cells and NK cells, by active specific immunotherapy.

A method for enhancing or inducing an immune response to WT1 is disclosed. In particular, the method comprises administering to a patient an immunogenic composition comprising an isolated polypeptide consisting of amino acids 1-249 of WT1 and a non-specific immune response enhancer.

Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1 polypeptide; or a T cell that specifically reacts with a WT1 polypeptide. Such compositions may be used, for example, for the prevention and treatment of metastatic diseases.

Provided is a dendritic cell therapeutic agent, and more particularly, a composition which include dendritic cells activated by peptides including a telomerase-derived peptide, the composition administered to treat an individual having disease and disorder symptoms which require target-specific treatments. Also, provided is a therapeutic method effective on diseases requiring target-specific immunotherapy. In the method, co-administration of the dendritic cell therapeutic agent and an immunotherapeutic agent including the telomerase-derived peptide results in decreased factors causing one of the disease and disorder symptoms requiring the target-specific treatment, such as cancer, in a tumor disease treatment.

Contiguous overlapping peptides (COPs) for the treatment of allergic patients by Specific Immunotherapy (SIT) are provided from the sequence of the major allergens of house dust mites Der p 1 and Der p 2. Such peptides while providing all potential T cell epitopes are devoid of the three dimensional structure of the original allergen, therefore reducing their ability to bind IgE. As a result increased amounts of COPs can be administered per injection, therefore reducing both the number of injections and the length of the immunotherapy treatment.

The invention discloses a stable film agent medicinal composition containing an allergen, which comprises a theoretically effective amount of allergen, a film-forming material and a pharmaceutically acceptable carrier. In a preferable embodiment, the film-forming material accounts for 30 to 99 percent of the mass of the entire film agent medicinal composition. In addition, the invention also relates to a preparation method of the film agent medicinal composition. The application of the allergen film agent makes the standard medicament administration in allergen specific immunotherapy convenient.

Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1 polypeptide; or a T cell that specifically reacts with a WT1 polypeptide. Such compositions may be used, for example, for the prevention and treatment of metastatic diseases.

Heat-denatured allergen compositions of bee venom, grass pollen, birch pollen, and cat dander or hair for use in allergen-specific immunotherapy.

The invention discloses a pharmaceutical composition for chemotherapy and immunotherapy combined treatment. The pharmaceutical composition is prepared from: a first component alginate and a second component chemotherapeutic drug; the alginate can form a porous gel with calcium ions in a body, and the alginate is one or more of sodium alginate, potassium alginate and ammonium alginate; and the second component chemotherapeutic drug can cause immungentic cell death. The pharmaceutical composition belongs to an efficient tumor-specific immunotherapy program, the tumor in situ can be effectively killed, and the growth of distant metastatic tumors and the recurrence probability of tumor can be suppressed and reduced through immune response.

The present invention provides a method to produce variant recombinant mite Group 1 proteins with properties suitable for accelerated, specific immunotherapy. The variants of the present invention have greatly reduced IgE binding activity, but little or no loss in the ability to stimulate T cells in allergic individuals. The present invention also relates to a variant mite Group 1 protein obtained by such a method, and the use of such a variant mite Group 1 protein to reduce an allergic response to a mite Group 1 protein. The present invention also includes novel mite Group 1 nucleic acid molecules, proteins, recombinant molecules, and recombinant cells, as well as uses thereof.

The present invention provides in vitro and in vivo diagnostic tests and methods for determining the safety, efficacy, or outcome of allergen-specific immunotherapy (SIT) in a patient. The present invention also provides for the measurement of allergen specific IgG and IgE in a patient tissue sample, or extract thereof, or in a biological fluid or blood sample, and determining whether the allergen-specific immunoglobulins contained in the patient sample(s), upon injection into an allergen-sensitized animal, will protect the animal following challenge with the allergen. The invention also provides methods for determining whether a patient suffering from an allergy is responsive to therapy with one or more therapeutic antibodies specific for the allergen.